Noninvasive surveillance with multitarget stool DNA testing or fecal immunochemical testing (FIT) could potentially match colonoscopy for reducing long-term ...

More than 10% of fecal immunochemical test (FIT)–based colorectal cancer screening could not be processed due to unsatisfactory samples. Colorectal cancer (CRC) screening using the fecal ...

Commercial FITs can match NG-MSDT diagnostic results for CRC by lowering the positivity threshold, enhancing sensitivity while maintaining specificity. FITs are accessible, noninvasive CRC screening ...

Mayo Clinic researchers conducted a study comparing the efficacy of multitarget stool DNA tests to fecal immunochemical testing for colorectal cancer screening in Alaska Native people. Here are six ...

Annual fecal immunochemical test-based surveillance could be as effective as colonoscopies in reducing long-term colorectal cancer incidence and mortality, according to a recent study published in ...

Roughly 10% of fecal immunochemical tests (FIT) used for colorectal cancer (CRC) screening by a safety-net health system contained unsatisfactory samples that could not be processed. And fewer than ...

What if you didn't have to get a colonoscopy every decade from ages 45 to 75? No, this isn't an excuse to skip screening for colon cancer, which has been proven to save lives. But there are several ...

VANCOUVER, British Columbia -- The novel multitarget stool RNA test (ColoSense) showed high sensitivity for detecting colorectal neoplasia among adults ages 45 and older, according to the phase III ...

FIT (Faecal Immunochemical Test) is a test that looks for blood in a sample of your poo. It looks for tiny traces of blood that you might not be able to see, and which could be a sign of cancer.